Design, synthesis and in vivo anticonvulsant screening in mice of Novel phenylacetamides

European Journal of Medicinal Chemistry

Volumn 41, Issue 6, 2006, Pages 786-792

  Shindikar, A V ^a   Khan, F ^a   Viswanathan, C L ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

2 anilinophenylacetamides; Anticonvulsants; MES test; phenylacetamides; ScPTZ test

Indexed keywords

1 [[2 (PHENYLAMINO)PHENYL]ACETYL] 2 PYRROLIDINONE; 2 [2 (PHENYLAMINO)PHENYL]ACETAMIDE; 2 [[2 (PHENYLAMINO)PHENYL]ACETYL]HYDRAZINE; 2 [[2 (PHENYLAMINO)PHENYL]ACETYL]HYDRAZINE CARBOXAMIDE; 2 [[2 (PHENYLAMINO)PHENYL]ACETYL]HYDRAZINE THIOCARBOXAMIDE; ACETANILIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DENZIMOL; DEZINAMIDE; DIAZEPAM; FLUNARIZINE; LAMOTRIGINE; N [3 (2,6 DIMETHYL 1 PIPERIDINYL)PROPYL] ALPHA PHENYLBENZENEACETAMIDE; N ETHYL 2 [2 (PHENYLAMINO)PHENYL]ACETAMIDE; N PHENYL 2 [2 (PHENYLAMINO)PHENYL]ACETAMIDE; NAFIMIDONE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; REMACEMIDE; RUFINAMIDE; UNCLASSIFIED DRUG; ZONISAMIDE; AMIDE; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IN VIVO STUDY; LETHARGY; MALE; MOUSE; MOUSE STRAIN; NEUROTOXICITY; NONHUMAN; PHARMACOPHORE; PREDICTION; ROTAROD TEST; SEDATION; SEIZURE; STATISTICAL SIGNIFICANCE; TOXICITY TESTING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

AMIDES; ANIMALS; ANTICONVULSANTS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR; PHENYLACETATES; SPECTROPHOTOMETRY, INFRARED;

EID: 33744989670     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.03.013     Document Type: Article

References (16)

1. Jain S. Epilepsia 46 (2005) 46-47
2. Medina M.T., Duron R.M., Martinez L., Osorio J.R., Estrade A.L., Zuniga C., and Holden K.R. Epilepsia 46 (2005) 124-131
3. Rosenbloom D., and Upton A.R.M. Can. Med. Assoc. J. 128 (1983) 261-270
4. Brodie M.J., Dichter M.A., and Engl N. J. Med. 334 (1996) 168-175
5. Currey W.J., and Kulling D.L. Epilepsia 57 (1998) 513-520
6. Meldrum B.S. Epilepsia 37 (1996) S4
7. Taylor C.P. Curr. Pharm. Des. 2 (1996) 375-381
8. Roufos I., Hays S.J., Doolay D.J., Schwarz R.D., Campbell G.W., and Probert A.W. J. Med. Chem. 37 (1994) 268-274
9. Sarges R., Howard R.H., and Koe K.B. J. Med. Chem. 32 (1989) 437-444
10. Moser P., Sallmann A., and Wiesenberg I. J. Med. Chem. 33 (1990) 2358-2368
11. OECD (Organization for Economic Cooperation and Development) (1998), Guidelines, USA
12. Gallagher B.B. In: Vida J.A. (Ed). Anticonvulsants: A series of monographs Vol 15 (1977), Academic Press, London
13. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., and Swinyard E.A. Epilepsia 19 (1978) 409-428
14. Clark C.R., Wells M.J.M., Sansom R.T., Norris G.N., Dockens R.C., and Ravis W.R. J. Med. Chem. 27 (1984) 779-782
15. Litchfield J.T., and Wilcoxon F.A. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
16. Edafiogho I.O., and Scott K.R. In: Wolff M.E. (Ed). Burger's Medicinal Chemistry (1996), John Wiley & Sons, New York 175-260